Abstract
Purpose: The purpose of the present study was to analyze associations between different skeletal muscle quality parameters and survival in patients with hepatocellular carcinoma (HCC) undergoing treatment with transarterial chemoembolization (TACE).
Methods: We retrospectively enrolled 784 treatment-naïve patients with HCC undergoing TACE at six tertiary care centers between 2010 and 2020. Intramuscular adipose tissue (IMAT) and skeletal muscle density (SMD) were estimated. Myosteatosis was defined as SMD < 28.0 HU for men and < 23.8 HU for women. Furthermore, albumin-SMD score (ADS) was calculated as follows: serum albumin (g/dL) × SMD (HU). To assess the impact of muscle quality on survival, Cox regression model was used. Kaplan-Meier curves were used for survival analysis. Parameters of skeletal muscle quality were compared in univariate and multivariate regression analyses, adjusted for established risk factors.
Results: In the overall sample, survivors had higher SMD and ADS in comparison to non-survivors. Patients with low ADS had a lower OS than patients with high ADS (8.4 vs 14.3 months, p < 0.001). In alcohol-induced HCC, none of the analyzed parameters of muscle quality influenced survival. In viral induced HCC, patients with low ADS had lower OS than patients with high ADS (8.8 vs 15.7 months, p < 0.001). In patients with non-alcoholic steatohepatitis (NASH), none of the analyzed parameters of muscle quality influenced survival.
Conclusions: Low ADS is an independent predictor of worse OS in patients with viral-induced HCC undergoing treatment with TACE. In alcohol-induced and NASH-induced HCCs, parameters of muscle quality do not influence OS.
Introduction
Hepatocellular carcinoma (HCC) remains a significant global health challenge, ranking as a leading cause of cancer-related mortality. For patients diagnosed with intermediate-stage HCC, Transarterial Chemoembolization (TACE) is the standard of care. However, the clinical outcome for these patients varies widely, making the identification of reliable prognostic markers essential for personalized treatment planning.
While traditional staging systems focus on tumor burden and liver function, there is increasing recognition of "host factors" in determining survival. Specifically, muscle quality parameters such as sarcopenia (loss of muscle mass) and myosteatosis (fatty infiltration of muscle) have emerged as potential biomarkers. This study introduces the Albumin-SMD Score (ADS), a novel tool that integrates nutritional status with physical muscle quality to provide a more comprehensive survival roadmap.
Methodology and Patient Cohort
This retrospective multicenter study analyzed data from 784 treatment-naïve patients who underwent TACE at six German tertiary care hospitals between 2010 and 2020. The cohort was predominantly male (82.3%) with a median age of 67 years. The primary etiologies for HCC were alcohol-induced (42.5%), viral-induced (29.2%), and non-alcoholic steatohepatitis (NASH, 5.4%).
Researchers utilized baseline CT scans to perform body composition segmentation, measuring Skeletal Muscle Density (SMD) and Intramuscular Adipose Tissue (IMAT) in Hounsfield Units (HU). The Albumin-SMD Score (ADS) was derived by multiplying serum albumin (g/dL) by the SMD (HU). Survival analysis was conducted using Cox regression models and Kaplan-Meier curves, adjusting for established risk factors like BCLC stage and bilirubin levels.
Key Results
The study revealed that ADS is a robust predictor of overall survival (OS). In the total patient sample, those with a low ADS had a median survival of 8.4 months, significantly shorter than the 14.3 months observed in the high ADS group (p < 0.001).
Statistical analysis across different time points showed that survivors consistently maintained higher ADS values compared to non-survivors at 1, 2, and 3 years post-treatment. Notably, while muscle density and ADS were significant predictors, IMAT (fat around the muscle) did not show a significant influence on survival, suggesting that intracellular muscle degeneration is a more critical biological marker.
The Impact of Etiology
A critical finding of this research is that the prognostic value of muscle quality is highly dependent on the underlying cause of the liver disease:
- Viral-induced HCC: ADS was a powerful predictor, with high-ADS patients living nearly twice as long as low-ADS patients (15.7 vs 8.8 months).
- Alcohol and NASH-induced HCC: In these subgroups, muscle quality parameters did not significantly influence survival. The authors hypothesize a "floor effect," where metabolic damage in these patients may result in uniformly poor muscle quality, reducing its utility as a differentiator.
Discussion and Clinical Implications
The synergy of "fuel" (albumin) and "engine" (muscle density) makes the ADS a unique prognostic tool. Albumin reflects the liver's synthetic function and systemic inflammation, while muscle density serves as a proxy for metabolic health and the production of anti-cancer myokines.
Despite the strong findings, the study has limitations, including its retrospective design and the relatively small size of the NASH subgroup. Furthermore, while ADS identifies high-risk patients, it remains to be seen if interventions such as nutritional support or exercise can improve outcomes for those with low scores. Future prospective trials are needed to determine if pre-treatment optimization of ADS can translate into better survival for HCC patients undergoing TACE.
Summary updated